The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain
European Journal of Pain · 2026-11 · 30 (10)
DOI: 10.1002/ejp.70448 ↗Abstract
ABSTRACT Background Dichotomous responder outcomes, including ≥ 30% and ≥ 50% pain reduction, patient‐reported pain relief, and Patient Global Impression of Change (PGIC), are widely used in trials assessing interventions for neuropathic pain and have been suggested to be comparable, but their differences and influence on estimated treatment effects remain uncertain. Methods The study presents secondary analyses of 222 double‐blind RCTs in neuropathic pain. Trials assessing drugs with recommended or inconclusive recommendations reporting at least two different dichotomous outcomes were included. Risk differences, numbers needed to treat (NNT), and relative risks were calculated. Results Ninety‐one trials were included. Across 76 trials, the risk difference was higher for ≥ 30% than ≥ 50% pain reduction (difference 0.023, 95% CI 0.012–0.034; p < 0.001), corresponding to lower NNTs for ≥ 30% pain reduction (8.8 vs. 11.1). PGIC‐based outcomes yielded numerically lower NNTs than ≥ 50% pain reduction and were similar to ≥ 30% pain reduction, although variability was substantial. Within 31 trials reporting all outcomes, ≥ 30% pain reduction and PGIC showed comparable NNTs on average, whereas ≥ 50% pain reduction consistently produced higher NNTs. Comparisons involving pain relief scales were limited by sparse data and heterogeneity. Conclusions Estimated treatment effects in neuropathic pain trials depend on the responder definition used. Outcomes based on ≥ 50% pain reduction yield systematically higher NNTs than ≥ 30% pain reduction and PGIC, indicating lower assay sensitivity. Standardization of outcome measures may improve interpretability and comparability of analgesic efficacy. Significance Indicating the main aspects where this work adds significantly to existing knowledge in the field, and if appropriate to clinical practice. We show that stricter responder thresholds (≥ 50% pain reduction) attenuate detectable treatment effects compared with ≥ 30% pain reduction. This has direct implications for meta‐analyses and comparisons of treatment effects as well as for clinical trials, as suboptimal endpoint choice may contribute to underpowered trials and premature discontinuation of potentially effective therapies.
EUVIMED